HPM Partners LLC lowered its stake in shares of Davita Inc (NYSE:DVA) by 13.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 22,185 shares of the company’s stock after selling 3,460 shares during the period. HPM Partners LLC’s holdings in Davita were worth $1,541,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors also recently bought and sold shares of DVA. Vigilant Capital Management LLC lifted its holdings in Davita by 250.0% during the second quarter. Vigilant Capital Management LLC now owns 2,100 shares of the company’s stock worth $146,000 after buying an additional 1,500 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. purchased a new stake in Davita during the second quarter worth $206,000. IBM Retirement Fund purchased a new stake in Davita during the first quarter worth $212,000. IFG Advisory LLC purchased a new stake in Davita during the second quarter worth $213,000. Finally, Pendal Group Ltd purchased a new stake in Davita during the first quarter worth $242,000. Institutional investors own 87.80% of the company’s stock.
Shares of DVA opened at $70.78 on Friday. Davita Inc has a 12 month low of $52.51 and a 12 month high of $80.71. The company has a quick ratio of 1.88, a current ratio of 1.90 and a debt-to-equity ratio of 1.82. The firm has a market cap of $11.28 billion, a PE ratio of 21.32, a price-to-earnings-growth ratio of 1.01 and a beta of 1.10.
A number of research firms have weighed in on DVA. JPMorgan Chase & Co. upgraded Davita from an “underweight” rating to a “neutral” rating in a report on Thursday. Zacks Investment Research upgraded Davita from a “sell” rating to a “hold” rating in a report on Tuesday, August 7th. Finally, William Blair restated a “buy” rating on shares of Davita in a report on Wednesday, June 6th. Five analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $82.13.
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Featured Article: Do You Need a Fiduciary?
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Davita Inc (NYSE:DVA).
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.